Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation

Indian Journal of Psychiatry
Daya Ram, S Gandotra

Abstract

Untreated perinatal depression and anxiety disorders are known to have significant negative impact on both maternal and fetal health. Dilemmas still remain regarding the use and safety of psychotropics in pregnant and lactating women suffering from perinatal depression and anxiety disorders. The aim of the current paper was to review the existing evidence base on the exposure and consequences of antidepressants, anxiolytics, and hypnotics in women during pregnancy and lactation and to make recommendations for clinical decision making in management of these cases. We undertook a bibliographic search of Medline/PubMed (1972 through 2014), Science Direct (1972 through 2014), Archives of Indian Journal of Psychiatry databases was done. References of retrieved articles, reference books, and dedicated websites were also checked. The existing evidence base is extensive in studying multiple outcomes of the antidepressant or anxiolytic exposure in neonates, and some of the findings appear conflicting. Selective serotonin reuptake inhibitors are the most researched antidepressants in pregnancy and lactation. The available literature is criticized mostly on the lack of rigorous well designed controlled studies as well as lacunae in the me...Continue Reading

References

Sep 21, 1979·Science·C V VorheesR E Butcher
Oct 1, 1979·The Journal of Nervous and Mental Disease·A J Gelenberg
Jan 1, 1991·International Journal of Psychiatry in Medicine·S Misri, K Sivertz
Feb 1, 1991·British Journal of Clinical Pharmacology·S WrightJ J Ashford
Jul 1, 1990·Journal of Affective Disorders·A BuistL Dennerstein
Apr 1, 1990·Journal of Paediatrics and Child Health·S SinghO N Bhakoo
Jan 1, 1989·European Journal of Clinical Pharmacology·G PonsG Olive
Jan 1, 1987·European Journal of Clinical Pharmacology·M Wretlind
Sep 1, 1986·British Journal of Clinical Pharmacology·R K VerbeeckE A McKenna
Dec 1, 1986·The American Journal of Psychiatry·H C Stancer, K L Reed
Dec 1, 1986·Journal of Clinical Psychopharmacology·W B Pittard, W O'Neal
Jul 15, 1985·American Journal of Obstetrics and Gynecology·C K Heritage, M D Cunningham
Oct 1, 1985·British Journal of Anaesthesia·R J Summerfield, M S Nielsen
Nov 1, 1985·British Journal of Clinical Pharmacology·J KempL P Hackett
Mar 4, 1972·Lancet·M J PatrickP Reavey
Jun 3, 1972·Lancet·R Erkkola, J Kanto
Sep 1, 1972·Indian Journal of Pediatrics·B SharmaN L Sharma
Sep 1, 1972·The Journal of Pediatrics·W T ShearerR E Marshall
Jan 1, 1980·Pharmacology & Therapeutics·A Vernadakis, K K Parker
Apr 4, 1981·British Medical Journal·A G WhitelawI R McFadyen
Oct 1, 1984·Journal of Clinical Pharmacology·J M HilbertN Zampaglione
Jan 1, 1982·Psychopharmacology·L Brixen-RasmussenA Jørgensen
Jun 19, 1982·British Medical Journal·L CoweS Dawling
Jul 1, 1980·The American Journal of Psychiatry·T F Bader, K Newman
Aug 1, 1980·The Journal of Pediatrics·C G Falterman, C J Richardson
Feb 1, 1995·Journal of Clinical Psychopharmacology·R I Shader, D J Greenblatt
Mar 1, 1995·Clinical Pharmacokinetics·G M Pacifici, R Nottoli
Dec 14, 1994·JAMA : the Journal of the American Medical Association·R Bromiker, M Kaplan
Nov 1, 1993·Journal of the American Academy of Child and Adolescent Psychiatry·B M LesterW Oh
Oct 1, 1993·The American Journal of Psychiatry·K L WisnerS B Wheeler
May 5, 1993·JAMA : the Journal of the American Medical Association·A PastuszakC Woodland
Sep 1, 1995·British Journal of Clinical Pharmacology·C Y OoP J McNamara
May 1, 1996·The American Journal of Psychiatry·L L AltshulerJ Mintz
Dec 1, 1995·Journal of Clinical Psychopharmacology·D J Goldstein
Oct 3, 1996·The New England Journal of Medicine·C D ChambersK L Jones
Feb 1, 1996·Journal of Clinical Psychopharmacology·L L Altshuler, V C Hendrick
Jan 1, 1996·Journal of Clinical Pharmacology·A TaddioG Koren
Jan 23, 1997·The New England Journal of Medicine·I NulmanG Koren
Mar 1, 1997·The Journal of Clinical Psychiatry·O K MammenS B Wheeler
Jul 11, 1997·Pediatrics·M J MhannaS D Izatt

❮ Previous
Next ❯

Citations

Jan 28, 2017·Journal of Affective Disorders·Michael PaulzenGeorgios Schoretsanitis
Jan 12, 2017·Trends in psychiatry and psychotherapy·Renata de Melo Felipe, Ygor Arzeno Ferrão
Aug 6, 2020·British Journal of Clinical Pharmacology·Aurélie CabaillotCatherine Laporte
Feb 18, 2020·Psychopharmacology·Beatriz Peñalver BernabéJack A Gilbert
Dec 23, 2016·Obstetrical & Gynecological Survey·Salvatore Giovanni VitaleAntonio Bruno
Apr 9, 2021·Expert Review of Neurotherapeutics·Bhuvaneshwari SethuramanKrishnamachari Srinivasan

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapies
for
pharmacotherapy
sedation

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Human Lactation : Official Journal of International Lactation Consultant Association
Kathleen Kendall-Tackett, Thomas W Hale
The Australian and New Zealand Journal of Psychiatry
Adaobi UdechukuKlara Szego
Psychopharmacology Bulletin
D Jeffrey Newport, Zachary N Stowe
© 2021 Meta ULC. All rights reserved